Lijuan P. Chen
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications
Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 28, 2026
Synthesis and evaluation of mitochondrion-targeted tetraphenylethylene-based photosensitizer.
Journal: Bioorganic chemistry
Published: December 22, 2025
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.
Journal: Therapeutic advances in hematology
Published: August 05, 2025
Correction: TAK1 inhibition by natural cyclopeptide RA-V promotes apoptosis and inhibits protective autophagy in Kras-dependent non-small-cell lung carcinoma cells.
Journal: RSC advances
Published: July 07, 2025
Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 Inhibitors.
Journal: Journal of medicinal chemistry
Published: June 18, 2025
Predicting the Brain-To-Plasma Unbound Partition Coefficient of Compounds via Formula-Guided Network.
Journal: Journal of chemical information and modeling
Published: May 09, 2025
Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy.
Journal: European journal of medicinal chemistry
Published: April 10, 2025
Identification of a ligand-binding site on tubulin mediating the tubulin-RB3 interaction.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2025
Comparative analysis of rapid alkalinization factor peptide-triggered plant immunity in citrus and closely related species.
Journal: Plant physiology and biochemistry : PPB
Published: February 18, 2025
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
Journal: Acta pharmaceutica Sinica. B
Published: October 30, 2024
A structure-based framework for selective inhibitor design and optimization.
Journal: Communications biology
Published: October 21, 2024
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
Journal: Signal transduction and targeted therapy
Published: October 02, 2024
Last Updated: 09/26/2026